Neonmind’s NEO-002 artificial psilocybin prospect will be examined to be a low-dose procedure to manage and suppress affected individual urge for food. The business has secured pharmaceutical grade artificial psilocybin from Psygen and anticipates initiating a Phase I/II evidence-of-principle research for NEO-001 in the in the vicinity of long https://englandq999sle2.muzwiki.com/user